Treatment in Autoimmune Disease
Anokion is an innovative immune tolerance company focused on providing a more effective approach to treating autoimmune disease. Our proprietary immune tolerance platform features proteins, or antigens, that are engineered to deliver precise, targeted disease therapy, without the side effects of broad immunosuppression. Anokion’s antigen-specific platform can be translated to virtually any antigen-mediated disease, with widespread potential across multiple clinical applications.
- September 24, 2020
Anokion Announces FDA Clearance of IND Application for ANK-700 for the Treatment of Multiple Sclerosis| Read More
- September 22, 2020
Anokion Announces Expansion of Exclusive Collaboration with Bristol Myers Squibb to Develop Novel Treatments for Autoimmune Diseases| Read More